08:07 AM EDT, 09/23/2025 (MT Newswires) -- Microbix Biosystems ( MBXBF ) Tuesday said a program to support rapid accurate identification of patients who carry gene-variants that may impede the effectiveness of an antiplatelet (anti-clotting) drug Clopidogrel is now "live."

This external quality assessment (EQA) program is to help ensure the proficiency of sites performing point-of-care tests. Over 20% of people carry these gene variants that can lead to over-dosing or under-dosing of the drug, the company said.

Antiplatelet drugs are commonly prescribed to persons deemed at-risk of heart attack, stroke, pulmonary embolism, deep vein thrombosis, peripheral arterial occlusions, or atrial fibrillation. It is estimated that over 15 million prescriptions for Clopidogrel are written in the U.S. each year.